Search Result

Results for "

adipocytes+differentiation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (4) Amine N-methyltransferase (1) AMPK (3) Amyloid-β (2) Apoptosis (6) Bacterial (2) c-Myc (1) Calcium Channel (1) Carnitine Palmitoyltransferase (CPT) (1) Caspase (2) Chemerin Receptor (2) COX (2) Endogenous Metabolite (4) ERK (4) FABP (1) Fatty Acid Synthase (FASN) (1) Fungal (1) Glutamate Dehydrogenase (GLDH) (1) HIV (2) Insecticide (1) Integrin (2) Isotope-Labeled Compounds (1) Lactate Dehydrogenase (1) Lipase (1) MDM-2/p53 (1) NF-κB (1) PARP (3) PDHK (1) PGC-1α (1) Phosphatase (1) PI3K (2) PKA (1) PKC (2) PPAR (15) Reactive Oxygen Species (ROS) (5) Reference Standards (5) Sirtuin (4) STAT (2) Stearoyl-CoA Desaturase (SCD) (1) Toll-like Receptor (TLR) (2) Tryptophan Hydroxylase (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (4) Infection (6) Inflammation/Immunology (11) Metabolic Disease (28) Neurological Disease (3)

By Targets:

Akt (4)

Amine N-methyltransferase (1)

AMPK (3)

Amyloid-β (2)

Apoptosis (6)

Bacterial (2)

c-Myc (1)

Calcium Channel (1)

Carnitine Palmitoyltransferase (CPT) (1)

Caspase (2)

Chemerin Receptor (2)

COX (2)

Endogenous Metabolite (4)

ERK (4)

FABP (1)

Fatty Acid Synthase (FASN) (1)

Fungal (1)

Glutamate Dehydrogenase (GLDH) (1)

HIV (2)

Insecticide (1)

Integrin (2)

Isotope-Labeled Compounds (1)

Lactate Dehydrogenase (1)

Lipase (1)

MDM-2/p53 (1)

NF-κB (1)

PARP (3)

PDHK (1)

PGC-1α (1)

Phosphatase (1)

PI3K (2)

PKA (1)

PKC (2)

PPAR (15)

Reactive Oxygen Species (ROS) (5)

Reference Standards (5)

Sirtuin (4)

STAT (2)

Stearoyl-CoA Desaturase (SCD) (1)

Toll-like Receptor (TLR) (2)

Tryptophan Hydroxylase (1)

By Research Areas:

Cancer (12)

Cardiovascular Disease (4)

Infection (6)

Inflammation/Immunology (11)

Metabolic Disease (28)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0704

Agrimol B 1 Publications Verification	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial	Infection Metabolic Disease Cancer
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27 .

HY-N2551

Vitamin U chloride S-Methylmethionine sulfonium chloride	Others	Inflammation/Immunology
Vitamin U (S-Methylmethionine sulfonium) chloride is an orally active anti-ulcer agent with antioxidant activity. Vitamin U inhibits adipocyte differentiation. Vitamin U promotes skin wound healing.Vitamin U can be used in the research of gastrointestinal ulceration .

HY-163316

SIRT4-IN-1 2 Publications Verification	Sirtuin Glutamate Dehydrogenase (GLDH) PDHK	Metabolic Disease Cancer
SIRT4-IN-1 is a selective and potent Sirtuin 4 (Sirt4) inhibitor with an IC₅₀ of 16 μM for hSirt4. SIRT4-IN-1 also inhibits hSirt1, hSirt2, hSirt3, hSirt4 and hSirt6. SIRT4-IN-1 competes with acyl peptide substrate for Sirt4's acyl binding site, and is noncompetitive with NAD ⁺. SIRT4-IN-1 increases glutamate dehydrogenase (GDH) activity and rescues pyruvate dehydrogenase (PDH) activity. SIRT4-IN-1 inhibits adipocyte differentiation and suppresses Sirt4 overexpression-induced increased differentiation. SIRT4-IN-1 can be used for the researches of cancer and metabolic disease .

HY-B1890

(±)-Catechin 1 Publications Verification rel-Cianidanol; rel-Catechuic acid	COX	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
(±)-Catechin (rel-Cianidanol) is the racemate of the green tea polyphenol Catechin. Catechin has anticancer activity and induces apoptosis. (±)-Catechin has two forms, (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 1.4 μM. (-)-Catechin can effectively promote hBM-MSC adipocyte differentiation and increase adiponectin and PPARγ levels. (±)-Catechin has anti-tumor, anti-obesity, anti-diabetic, anti-cardiovascular, anti-infectious, hepatoprotective and neuroprotective effects .

HY-B1898

Metadoxine	PKA	Metabolic Disease
Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway.

HY-20019

L-165041 2 Publications Verification	PPAR	Metabolic Disease
L-165041 is a cell permeable PPARδ agonist, with K_is of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

HY-46866

Isoegomaketone	Apoptosis Caspase PARP	Metabolic Disease Inflammation/Immunology Cancer
Isoegomaketone is an orally active apoptosis inducer and radiosensitizer. Isoegomaketone regulates multiple key signaling pathways such as PI3K/AKT/mTOR, NF-κB, MAPK, cleaves Caspase family proteins and PARP, and modulates Bax, AIF and endoplasmic reticulum stress proteins. Isoegomaketone also induces autophagy and keratinocyte proliferation, effectively reduces the levels of inflammatory factors and oxidative stress, inhibits adipocyte differentiation, and resensitizes TRAIL-resistant cancer cells. Isoegomaketone can be applied to research related to colorectal cancer, melanoma, lung cancer, prostate cancer, liver cancer, as well as rheumatoid arthritis and obesity .

HY-N2110

Phellopterin	Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV	Inflammation/Immunology
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .

HY-128400

4'-Methoxychalcone	PARP	Metabolic Disease Cancer
4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-116538

(10E,12Z)-Octadeca-10,12-dienoic acid 1 Publications Verification trans-10,cis-12 CLA2	Endogenous Metabolite PPAR NF-κB Stearoyl-CoA Desaturase (SCD) Lipase	Metabolic Disease Inflammation/Immunology Cancer
(10E,12Z)-Octadeca-10,12-dienoic acid (trans-10,cis-12 CLA2) is an orally active PPARα activator and inhibits *adipocyte* differentiation. (10E,12Z)-Octadeca-10,12-dienoic acid and its downstream metabolites have various antioxidant and antitumor activities. (10E,12Z)-Octadeca-10,12-dienoic acid can induce proinflammatory cytokines and chemokines, which would lead to decreased adipogenesis and insulin resistance in adipose tissue. (10E,12Z)-Octadeca-10,12-dienoic acid can affect many aspects of milk fat synthesis. (10E,12Z)-Octadeca-10,12-dienoic acid reduces expression of lipogenic enzymes and inhibits the desaturation of fatty acids. (10E,12Z)-Octadeca-10,12-dienoic acid can reduce lipoprotein lipase (LPL) activity in cultured 3T3-L1 adipocytes and enhance triacylglycerol release from these cells. (10E,12Z)-Octadeca-10,12-dienoic acid decreases the expression of hepatic stearoyl-CoA desatyrase mRNA in mice. (10E,12Z)-Octadeca-10,12-dienoic acid is associated with changes in mucosal NF-κB and Cyclin D1 protein levels in mice .

HY-W109613

Methyl dehydroabietate	Bacterial PPAR Fungal	Infection Metabolic Disease
Methyl dehydroabietate is an orally active resin acid. Methyl dehydroabietate disrupts microbial cell walls and exhibits significant antibacterial activity. Methyl dehydroabietate induces the expression of PPARα in the liver and PPARγ in adipose tissue, and promotes adipocyte differentiation. Methyl dehydroabietate improves insulin resistance, reduces TNFα levels, and alleviates adipocyte hypertrophy and hepatic steatosis in obese mice. Methyl dehydroabietate can be used in research related to obesity, insulin resistance and hepatic steatosis .

HY-P1844A

Chemerin-9 (149-157) TFA 4 Publications Verification	Chemerin Receptor Akt ERK Reactive Oxygen Species (ROS) Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism .

HY-B1890R

(±)-Catechin (Standard) rel-Cianidanol (Standard); rel-Catechuic acid (Standard)	Reference Standards COX	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
(±)-Catechin (Standard) is the analytical standard of (±)-Catechin. This product is intended for research and analytical applications. (±)-Catechin (rel-Cianidanol) is the racemate of the green tea polyphenol Catechin. Catechin has anticancer activity and induces apoptosis. (±)-Catechin has two forms, (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. (-)-Catechin can effectively promote hBM-MSC adipocyte differentiation and increase adiponectin and PPARγ levels. (±)-Catechin has anti-tumor, anti-obesity, anti-diabetic, anti-cardiovascular, anti-infectious, hepatoprotective and neuroprotective effects .

HY-W012865

Tartronic acid	Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite FABP PPAR	Metabolic Disease
Tartronic acid, a dicarboxylic acid derive, is an inhibitor of the transformation of carbohydrates into fat under fat-deficient diet conditions. Tartronic acid promotes 3T3-L1 adipocyte differentiation by increasing the protein expression of FABP-4, PPARγ and SREBP-1. Tartronic acid promotes de novo lipogenesis and inhibits CPT-1β by upregulating acetyl-CoA and malonyl-CoA. Tartronic acid promotes weight gain and induces adipocyte hypertrophy in epididymal white adipose tissue and lipid accumulation in the livers of high-fat diet induced obese mice. Tartronic acid can be used for lipid metabolic disease research .

HY-N2177

3-Dehydrotrametenolic acid	Lactate Dehydrogenase Apoptosis	Cancer
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity .

HY-172609

SL-176	Phosphatase Apoptosis MDM-2/p53 Caspase	Metabolic Disease Cancer
SL-176 is a PPM1D (Wip1) inhibitor. SL-176 inhibits lipid droplet formation, downregulates the mRNA and protein expression of PPARγ and C/EBPα, and blocks adipocyte differentiation. SL-176 induces G2/M cell cycle arrest, apoptosis and inhibits cell proliferation in breast cancer cells overexpressing PPM1D, and activates components of the p53 pathway. SL-176 suppresses tumor growth in a zebrafish model of neuroblastoma. SL-176 is applicable to research related to obesity, breast cancer and neuroblastoma .

HY-102082

Adenosine N1-oxide	Others	Inflammation/Immunology
Adenosine N1-oxide is an oral active anti-inflammatory agent, and can be isolated from royal jelly. Adenosine N1-oxide promotes osteogenic and adipocyte differentiation .

HY-124822

COH-SR4 2 Publications Verification	AMPK	Metabolic Disease Cancer
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders .

HY-N3027

Soyasaponin Aa 1 Publications Verification	PPAR Reactive Oxygen Species (ROS)	Metabolic Disease
Soyasaponin Aa is a soyasaponin that can be found in soy. Soyasaponin Aa suppresses PPARγ transcriptional activity, reduces PPARγ and C/EBPα expression, inhibits adipocyte differentiation and lipid accumulation, and reduces adipogenic marker gene expression. Soyasaponin Aa reduces hydrogen peroxide-induced reactive oxygen species (ROS) production and malondialdehyde levels. Soyasaponin Aa exhibits cellular antioxidant activity. Soyasaponin Aa can be used for the research of obesity .

HY-P1844

Chemerin-9 (149-157) 4 Publications Verification	Chemerin Receptor Akt ERK Reactive Oxygen Species (ROS) Amyloid-β	Inflammation/Immunology
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism .

HY-W339331

Flubendiamide NNI-0001	Insecticide Calcium Channel Reactive Oxygen Species (ROS) Apoptosis	Infection Metabolic Disease
Flubendiamide (NNI-0001) is an orally active phthalic diamide insecticide that acts by targeting insect ryanodine receptors (RyRs), causing insect muscle dysfunction, paralysis and death. Flubendiamide disrupts molting, metamorphosis and reproductive processes, induces oxidative stress by increasing the levels of ROS/RNS, MDA and 8OHdG and decreasing the levels of SOD, CAT and GST, activates the CncC/Maf apoptosis pathway, impairs calcium homeostasis, promotes adipogenesis, increases triglyceride accumulation, and upregulates the expression of regulatory factors for adipocyte differentiation and adipogenesis .

HY-101292

FK614	PPAR	Metabolic Disease
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .

HY-N2110R

Phellopterin (Standard)	Reference Standards Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Phellopterin (Standard) is the analytical standard of Phellopterin. Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting TLR4/NF-κB pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus.

HY-E70259

18:2 (n6) Coenzyme A triammonium	Endogenous Metabolite	Metabolic Disease
18:2 (n6) Coenzyme A triammonium is a Coenzyme A. 18:2 (n6) Coenzyme A triammonium can be used to determine the effects of lysophospholipid acyltransferase activities in adipocyte differentiation .

HY-N2961

Broussonin B	Others	Others
Broussonin B is a phenolic compound isolated from the stem barks of Broussonetia kanzinoki (Moraceae). Broussonin B inhibits adipocyte differentiation in 3T3-L1 cells .

HY-107217

Apo-12'-lycopenal	PPAR	Metabolic Disease
Apo-12'-lycopenal is a Lycopene (HY-N0287) metabolite. Apo-12'-lycopenal promotes adipocyte differentiation and adiponectin secretion via PPAR-γ activation .

HY-117597

YM440	PPAR	Metabolic Disease
YM440 is an orally active oxadiazolidinedione analog. YM440 ameliorates hyperglycemia without changing PPARy activity, adipocyte differentiation, or fat weight. YM440 is used in the study for non-insulin-dependent diabetes mellitus (NIDDM) .

HY-E70251

22:6 Coenzyme A Docosahexaenoyl coenzyme A triammonium	Endogenous Metabolite	Others
22:6 Coenzyme A (Docosahexaenoyl coenzyme A triammonium) is a coenzyme that contains 22 carbon atoms and 6 unsaturated bonds. 22:6 Coenzyme A can serve as an acyl substrate and is used in research on the effects of lysophospholipid acyltransferase activities in adipocyte differentiation .

HY-128400R

4'-Methoxychalcone (Standard)	PARP Reference Standards	Metabolic Disease Cancer
4'-Methoxychalcone (Standard) is the analytical standard of 4'-Methoxychalcone. This product is intended for research and analytical applications. 4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-20019R

L-165041 (Standard)	PPAR	Metabolic Disease
L-165041 (Standard) is the analytical standard of L-165041. This product is intended for research and analytical applications. L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

HY-156093

TPH1-IN-1	Tryptophan Hydroxylase	Metabolic Disease
TPH1-IN-1 (compound 40) is a xanthine derivative and an inhibitor of tryptophan hydroxylase TPH1 (IC₅₀: 110.1 nM). TPH1-IN-1 has good in vitro activity and liver microsome stability, and effectively inhibits adipocyte differentiation of T3-L1 cells .

HY-133556

IQZ23	AMPK	Metabolic Disease
IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC₅₀=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders .

HY-N7661

4β-Hydroxywithanolide E	PPAR	Metabolic Disease
4β-Hydroxywithanolide E, isolated from Physalis peruviana L., inhibits adipocyte differentiation of 3T3-L1 cells through modulation of mitotic clonal expansion. 4β-Hydroxywithanolide E is an adipogenesis inhibitor and inhibits PPARγ, C/EBPα, and the adipocyte-specific molecule aP2 mRNA expression .

HY-W743198

Adenosine N1-oxide-15N	Isotope-Labeled Compounds	Inflammation/Immunology
Adenosine N1-oxide- ¹⁵N is the ¹⁵N-labeled Adenosine N1-oxide (HY-102082). Adenosine N1-oxide is an oral active anti-inflammatory agent, and can be isolated from royal jelly. Adenosine N1-oxide promotes osteogenic and adipocyte differentiation .

HY-N3027R

Soyasaponin Aa (Standard)	Reference Standards PPAR Reactive Oxygen Species (ROS)	Metabolic Disease
Soyasaponin Aa (Standard) is the analytical standard of Soyasaponin Aa (HY-N3027). Soyasaponin Aa is a soyasaponin that can be found in soy. Soyasaponin Aa suppresses PPARγ transcriptional activity, reduces PPARγ and C/EBPα expression, inhibits adipocyte differentiation and lipid accumulation, and reduces adipogenic marker gene expression. Soyasaponin Aa reduces hydrogen peroxide-induced reactive oxygen species (ROS) production and malondialdehyde levels. Soyasaponin Aa exhibits cellular antioxidant activity. Soyasaponin Aa can be used for the research of obesity .

HY-172901

AMPK activator 17	AMPK	Cardiovascular Disease Metabolic Disease
AMPK activator 17 (Compound 10g) is an orally active AMPK activator. AMPK activator 17 has significant anti-adipogenic (IC₅₀: 3.4 μM) and dyslipidemia-modifying activities. AMPK activator 17 inhibits the early stages of adipocyte differentiation (mitotic clonal expansion) by activating the AMPK pathway. AMPK activator 17 can enhance mitochondrial function and fatty acid oxidation in mature adipocytes. AMPK activator 17 improves dyslipidemia by promoting reverse cholesterol transport. AMPK activator 17 can be used in the study of obesity and related metabolic diseases (such as type 2 diabetes and cardiovascular disease) .

HY-186163

CC-410	Amine N-methyltransferase	Metabolic Disease
CC-410 is a selective Nicotinamide N-methyltransferase (NNMT) inhibitor with a human IC₅₀ value of 1.6 µM. CC-410 impairs terminal adipocyte differentiation via glucocorticoid signaling network deregulation, inhibits adipogenesis and lipid accumulation with time-sensitive activity limited to early adipogenesis stages. CC-410 can be used for the researches of early-onset obesity, glucocorticoid-induced obesity .

HY-183094

AM73	PGC-1α	Metabolic Disease
AM73 is a PGC-1α1 stabilizer. AM73 increases the expression levels of Ucp1 and Cidea in brown adipocytes, and enhances basal mitochondrial respiration and uncoupled respiration. AM73 regulates hypoxia, brown adipocyte differentiation, carbohydrate metabolism and insulin signaling pathways in brown adipocytes. AM73 alters the thermogenic process of white adipocytes. AM73 is applicable to the research of obesity and related metabolic disorders .

HY-101292R

FK614 (Standard)	PPAR Reference Standards	Metabolic Disease
FK614 (Standard) is the analytical standard of FK614 (HY-101292). This product is intended for research and analytical applications. FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .

Cat. No.	Product Name	Target	Research Area